ORIN1001
Phase 1/2Completed 3 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Effect of Drug
Conditions
Effect of Drug
Trial Timeline
Jul 1, 2020 → Jan 30, 2025
NCT ID
NCT05154201About ORIN1001
ORIN1001 is a phase 1/2 stage product being developed by Fosun Pharma for Effect of Drug. The current trial status is completed. This product is registered under clinical trial identifier NCT05154201. Target conditions include Effect of Drug.
What happened to similar drugs?
2 of 4 similar drugs in Effect of Drug were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05154201 | Phase 1/2 | Completed |
Competing Products
20 competing products in Effect of Drug